Literature DB >> 12947545

[Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene].

Xinrong Liu1, Rouli Zhou, Qingyun Zhang, Ye Zhang, Genze Shao, Yueying Jin, Sha Zhang, Ming Lin, Jing'an Rui, Daxiong Ye.   

Abstract

OBJECTIVE: To identify and characterize the novel proteins encoded by a HCC-associated novel gene, LAPTM4B (lysosomeassociated protein transmembrane 4 beta).
METHODS: The novel proteins was identified by Western blot, immunohistochemistry and 2D electrophoresis; the molecular interactions were studied by co-immunoprecipitation.
RESULTS: LAPTM4B encoded two isoforms of proteins with molecular weight 35 x 10(3) and 24 x 10(3) and pI 9.07 and 4.65, respectively. The expression levels of LAPTM4B proteins in HCC tissues and cell lines were upregulated and related to differentiation, and most dramatically raised for 35 x 10(3) one. It was demonstrated that LAPTM4B--integrin alpha 6 and LAPTM4B--EGFR signaling complexes were formed when BEL-7402 cells were seeded on laminin substrate.
CONCLUSION: The LAPTM4B-35 protein is overexpressed in human HCC tissues and cell lines and may involve in signal transduction triggered by extracellular matrix via interaction with integrin alpha 6 and EGFR on cell surface.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12947545

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  21 in total

1.  Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4 beta associated with hepatocellular carcinoma.

Authors:  Xin-Rong Liu; Rou-Li Zhou; Qing-Yun Zhang; Ye Zhang; Yue-Ying Jin; Ming Lin; Jing-An Rui; Da-Xiong Ye
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

2.  Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma.

Authors:  Cong Peng; Rou-Li Zhou; Gen-Ze Shao; Jing-An Rui; Shao-Bin Wang; Ming Lin; Sha Zhang; Zi-Feng Gao
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

3.  [Serum LAPTM4B-35 protein as a novel diagnostic marker for hepatocellular carcinoma].

Authors:  Y Pang; S Zhang; H Yang; R L Zhou
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-18

4.  Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer.

Authors:  Han Tang; Hui Tian; Weiming Yue; Lin Li; Shuhai Li; Cun Gao; Libo Si; Lei Qi; Ming Lu
Journal:  Med Oncol       Date:  2014-05-11       Impact factor: 3.064

5.  LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.

Authors:  Hua Yang; Fu Xia Xiong; Ming Lin; Yu Yang; Xiu Nie; Rou Li Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-19       Impact factor: 4.553

6.  Association of LAPTM4B gene polymorphism with nasopharyngeal carcinoma susceptibility in a Chinese population.

Authors:  Bing Wang; Jianjun Xu; Rouli Zhou; Qingyun Zhang
Journal:  Med Oncol       Date:  2013-01-24       Impact factor: 3.064

7.  A role for the ubiquitin ligase Nedd4 in membrane sorting of LAPTM4 proteins.

Authors:  Ruth Milkereit; Daniela Rotin
Journal:  PLoS One       Date:  2011-11-11       Impact factor: 3.240

8.  LAPTM4B-35, a cancer-related gene, is associated with poor prognosis in TNM stages I-III gastric cancer patients.

Authors:  Xiaojing Cheng; Zhixue Zheng; Zhaode Bu; Xiaojiang Wu; Lianhai Zhang; Xiaofang Xing; Xiaohong Wang; Ying Hu; Hong Du; Lin Li; Shen Li; Rouli Zhou; Xian-Zi Wen; Jia-Fu Ji
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

9.  The relationship between LAPTM4B polymorphisms and cancer risk in Chinese Han population: a meta-analysis.

Authors:  Ling-Zi Xia; Zhi-Hua Yin; Yang-Wu Ren; Li Shen; Wei Wu; Xue-Lian Li; Peng Guan; Bao-Sen Zhou
Journal:  Springerplus       Date:  2015-04-15

10.  LAPTM4B allele *2 is associated with breast cancer susceptibility and prognosis.

Authors:  Xiaoyan Li; Xiangnan Kong; Xi Chen; Ning Zhang; Liyu Jiang; Tingting Ma; Qifeng Yang
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.